Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1020919 | 0.96 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2PKMUSP2POLB | |
| SCHEMBL1020152 | 0.95 | MEN1 (0.48) | ALDH1A1SMN1; SMN2PKMUSP2POLB | |
| SCHEMBL1020706 | 0.95 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2PKMUSP2POLB | |
| SCHEMBL1021297 | 0.95 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2PKMUSP2POLB | |
| SCHEMBL1020465 | 0.90 | CYP19A1 (0.47) | ALDH1A1SMN1; SMN2PKMUSP2POLB | |
| SCHEMBL1023771 | 0.89 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2PKMUSP2POLB | |
| SCHEMBL1020726 | 0.89 | MAPT (0.50) | ALDH1A1SMN1; SMN2PKMUSP2POLB | |
| SCHEMBL1022901 | 0.88 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2PKMUSP2POLB | |
| SCHEMBL2010437 | 0.86 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2PKMUSP2POLB | |
| SCHEMBL1020996 | 0.86 | GAA (0.44) | ALDH1A1SMN1; SMN2PKMUSP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960556-B2 | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | NV REMYND (BE) | 2011-06-14 | — | — | US | disclosed |
| EP-2094677-B1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | REMYND NV (BE) | 2011-01-12 | — | — | EP | disclosed |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | SNCA, PARK7, PRNP | ALDH1A1 608/4885SMN1; SMN2 8/4885PKM 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.